Summit Therapeutics Recognises 10th Annual Rare Disease Day
28 févr. 2017 07h00 HE
|
Summit Therapeutics PLC
OXFORD, United Kingdom, Feb. 28, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Receives Rare Pediatric Disease Designation From US FDA for Ezutromid in Treatment of Duchenne Muscular Dystrophy
27 sept. 2016 07h00 HE
|
Summit Therapeutics PLC
OXFORD, United Kingdom, Sept. 27, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Launches Online Resource on Utrophin Modulation for the Duchenne Muscular Dystrophy Community
12 sept. 2016 07h00 HE
|
Summit Therapeutics PLC
OXFORD, United Kingdom, Sept. 12, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Therapeutics Reports Financial Results for the Second Quarter Ended 31 July 2016 and Operational Progress
08 sept. 2016 07h00 HE
|
Summit Therapeutics PLC
Conference call to be held 1:00pm BST / 8:00am EDT OXFORD, United Kingdom, Sept. 08, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development...
Summit Reports Positive Phase 1 New Formulation Data and Outlines Route to Market Strategy for DMD Candidate Ezutromid
09 août 2016 07h00 HE
|
Summit Therapeutics PLC
New formulation of ezutromid achieved over a six-fold increase in maximum plasma levels in patientsPlans include incorporating new formulation into PhaseOut DMD trial OXFORD, United Kingdom, Aug. 09,...
FibroGen Announces Receipt of $62 Million License Payment from AstraZeneca
08 juil. 2016 04h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, July 08, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq:FGEN) (“FibroGen”), a research-based biopharmaceutical company, announced today that it has received a scheduled $62 million...
First Patient Enrolled in Summit’s PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Boys With DMD
17 juin 2016 07h00 HE
|
Summit Therapeutics PLC
OXFORD, United Kingdom, June 17, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
FibroGen to Present at the Goldman Sachs 37th Annual Global Healthcare Conference
06 juin 2016 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, June 06, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), announced that Chief Executive Officer, Thomas B. Neff, will be presenting at the Goldman Sachs 37th Annual Global...
Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2016 and Operational Progress
02 juin 2016 07h00 HE
|
Summit Therapeutics plc
OXFORD, United Kingdom, June 02, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...
FibroGen Reports Financial Results for the First Quarter of 2016
09 mai 2016 16h02 HE
|
FibroGen, Inc.
Continued Progress in Roxadustat Phase 3 Studies; Promising Interim Pancreatic Cancer Data –Webcast Conference Call Scheduled for 4:30pm EST Today– SAN FRANCISCO, May 09, 2016 (GLOBE NEWSWIRE)...